221 related articles for article (PubMed ID: 31045597)
21. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
[TBL] [Abstract][Full Text] [Related]
22. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
23. Potent Acid Suppression with PPIs and P-CABs: What's New?
Hunt RH; Scarpignato C
Curr Treat Options Gastroenterol; 2018 Dec; 16(4):570-590. PubMed ID: 30361857
[TBL] [Abstract][Full Text] [Related]
24. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitors: the beginning of the end or the end of the beginning?
Scarpignato C; Hunt RH
Curr Opin Pharmacol; 2008 Dec; 8(6):677-84. PubMed ID: 18840545
[TBL] [Abstract][Full Text] [Related]
26. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
27. Nighttime heartburn in patients with gastroesophageal reflux disease under routine care.
Nocon M; Labenz J; Jaspersen D; Leodolter A; Meyer-Sabellek W; Stolte M; Vieth M; Lind T; Malfertheiner P; Willich SN
Digestion; 2008; 77(2):69-72. PubMed ID: 18349541
[TBL] [Abstract][Full Text] [Related]
28. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).
Pohle T; Domschke W
Langenbecks Arch Surg; 2000 Aug; 385(5):317-23. PubMed ID: 11026702
[TBL] [Abstract][Full Text] [Related]
29. Gastroesophageal reflux disease: presentation and assessment of a common, challenging disorder.
Soll AH; Fass R
Clin Cornerstone; 2003; 5(4):2-14; discussion 14-7. PubMed ID: 15101491
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
[TBL] [Abstract][Full Text] [Related]
31. Potassium-competitive acid blockers and acid-related disorders.
Huang KZ; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2024 Jun; 31(3):107-114. PubMed ID: 38483115
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitors in the management of GERD.
Katz PO; Zavala S
J Gastrointest Surg; 2010 Feb; 14 Suppl 1():S62-6. PubMed ID: 19774429
[TBL] [Abstract][Full Text] [Related]
33. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
[TBL] [Abstract][Full Text] [Related]
34. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
Kawami N; Hoshino S; Hoshikawa Y; Takenouchi N; Umezawa M; Hanada Y; Kaise M; Iwakiri K
Digestion; 2018; 98(3):194-200. PubMed ID: 29870976
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Kindt S; Imschoot J; Tack J
Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
[TBL] [Abstract][Full Text] [Related]
37. Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.
Katz PO; Johnson DA
J Clin Gastroenterol; 2011 Oct; 45(9):748-54. PubMed ID: 21694609
[TBL] [Abstract][Full Text] [Related]
38. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
39. Treatment of gastroesophageal reflux disease.
Pettit M
Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949
[TBL] [Abstract][Full Text] [Related]
40. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and
Antequera CM; Orleck K; Jacob R; Kenneally A; Wright WL
Postgrad Med; 2024 Mar; 136(2):131-140. PubMed ID: 38385191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
